KROS compared with RMR: revenue, margins and what each company keeps, and the suppliers and customers both name

KROSKeros Therapeutics, Inc.

Mkt capRevenueRevenue

RMRRMR Group Inc.

Mkt capRevenueRevenue

Compare

KROSKeros Therapeutics, Inc.

RMRRMR Group Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only KROS 4

TAKTakeda Pharmaceuticalcustomer

—The General Hospitalunlistedsupplier

—Hansoh (Shanghai) Healthtechunlistedcustomer

—Takeda Pharmaceuticals U.S.Aunlistedcustomer

Shared 0

No shared counterparties.

Only RMR 13

SVCService Properties Trustcustomer

SEVNSeven Hills Realty Trustcustomer

—Sevnunlistedsupplier

—AlerisLife

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

unlistedcustomer

9 more · RMR chain ›

KROSKeros Therapeutics, Inc.

10.83▼−0.04%

Mkt cap$214.7MRevenue$367,000Q1 FY26Revenue$244MFY25

RMRRMR Group Inc.

16.70▲+0.51%

Regular sessionNov 4 '26

Mkt cap$535.7MRevenue$154MQ3 FY26Revenue$704MFY25

Compare

Regular sessionNov 4 '26

KROSKeros Therapeutics, Inc.

RMRRMR Group Inc.

10.83▼−0.04%

Price

16.70▲+0.51%

$214.7M

Mkt cap

$535.7M

Q1 FY26$367,000

Revenue

$154MQ3 FY26

FY25$244M

Revenue

$704MFY25

KROS10.83▼−0.04%vsRMR16.70▲+0.51%Regular sessionNov 4 '26